Genmab — April 2020

[Solsen]

Agree on WHO...

[Bulder]

(Bloomberg) -- Here is the full text of an emailed statement from Gilead Sciences Inc. after reports that the company’s experimental drug being tested in severe Covid-19 patients failed to show a positive result in a Chinese trial.
forts.

[Bulder]

We regret that the WHO prematurely posted information regarding the study, which has since been removed. The investigators in this study did not provide permission for publication of results. Furthermore, we believe the post included inappropriate characterizations of the study. forts.

[Bulder]

Importantly, because this study was terminated early due to low enrollment, it was underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease. forts.

[Bulder]

We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future. There are multiple ongoing Phase 3 studies that are designed to provide the additional data needed to determine the potential for remdesivir as a treatment for COVID-19. These studies will help inform whom to treat, when to treat and how long to treat with remdesivir. forts.

[Bulder]

The studies are either fully enrolled for the primary analysis or on track to fully enroll in the near future. slut

[Bulder]

Det drejer sig altså om et af de kinesiske studier (svær covid19), som blev afbrudt forleden pga manglende rekruttering.

[Solsen]

https://medwatch.dk/Medicinal___Biotek/article12095672.ece MedWatch på rem

[bibob]

God morgen.

[E_L]

Blood article : Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2020005288/454474/Daratumumab-Lenalidomide-Bortezomib-amp?redirectedFrom=fulltext

[E_L]

if i am not mistaken this is the data we saw at ASH?

[E_L]

insurance companies are proactively calling patients asking them to get daratumumab home infusion.... https://twitter.com/dhughesPharmD/status/1253383729172668416

[bibob]

E L. 07.52. I think you are right. - Submitted : February 13 . 2020. - Revision received : March 31. 2020. - Accepted: April 3. 2020.

[E_L]

ok, correct. also just checked with Genmab presentation. So that is really summer 2019 data i guess. Time for an ASCO update

[Sukkeralf]

ASCO could be huge for Genmab this year

[E_L]

i was wondering about that last weekend, probably a lot of various Dara regime updates? why do you think it would be huge?

[Bulder]

Don't forget tak-079.

[Sukkeralf]

hopefully dara in amyloidosis and if we are lucky also tisotumab vedotin and further updates on epcoritamab

[E_L]

yes, i was thinking the same. amyloidosis would even be a disappointment if it wouldn't be there . we'll get some insight next week.

[Sukkeralf]

Hopefully updates on JNJ Duobodies - at least JNJ61186372 would be nice